Biosplice Therapeutics
Biosplice Therapeutics is a clinical-stage biotechnology company developing lorecivivint; an injectable small-molecule CLK/DYRK-family inhibitor for knee osteoarthritis.
Funding history
About Biosplice Therapeutics
How much funding has Biosplice Therapeutics raised?
Biosplice Therapeutics has raised $799.0M in total funding. The most recent round was Series D.
Where is Biosplice Therapeutics headquartered?
Biosplice Therapeutics is headquartered in San Diego, CA.
What does Biosplice Therapeutics do?
Biosplice Therapeutics is a clinical-stage biotechnology company developing lorecivivint; an injectable small-molecule CLK/DYRK-family inhibitor for knee osteoarthritis.
Related terms
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated September 9, 2026.
🏷 Embed this badge
Building or fundraising? Add this to your site to show you're listed on SoCal.Startups — the link back helps other founders and investors find you here too.